NCT06943586View on ClinicalTrials.gov

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2029

Conditions
StrokeTransient Ischemic Attack (TIA)
Interventions
GENETIC

CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)

CYP2C19 is a gene that encodes an enzyme responsible for metabolizing several medications, including the antiplatelet drugs.

Trial Locations (1)

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER